Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 347

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1A
Chunk 347
---
 underlying Series B-1 Preferred Shares held by Pardeep Nijhawan Medicine Professional Corporation which are subject to a 19.99% beneficial ownership blocker.

63

			(6)

			Consists of (i) 2,748 common shares and (ii) 916 common shares issuable upon the conversion of restricted share units that have vested or will vest within sixty days of December 12, 2025 .

			(7)

			Consists of (i) 5,502 common shares, (ii) 2,858 common shares issuable upon exercise of options exercisable within sixty days of December 12, 2025 and (iii) 1,834 common shares issuable upon the conversion of restricted share units that have vested or will vest within sixty days of December 12, 2025.

			(8)
			
			Consists of (A)(i) 11,773 common shares issuable upon exercise of options exercisable within sixty days of December 12, 2025, (ii) 10,416 common shares held by Carlo Sistilli and (iii) 13,336 common shares issuable upon the conversion of restricted share units that have vested or will vest within sixty days of December 12, 2025 and (B) 522 common shares held by York-Cav Enterprises Inc. for which Carlo Sistilli, as President and Director, has sole voting and dispositive power over all such shares.

			(9)

			Consists of (i) 4,354 common shares, (ii) 67,662 common shares issuable upon exercise of options exercisable within sixty days of December 12, 2025, (iii) 303 common shares issuable upon exercise of warrants exercisable within sixty days of December 12, 2025 and (iv) 91,051 common shares issuable upon conversion of restricted share units that have vested or will vest within sixty days of December 12, 2025.

			(10)

			Consists of 14,448 common shares issuable upon conversion of restricted share units that have vested or will vest within sixty days of December 12, 2025.

			(11)

			Consists of (i) 2,486 common shares, (ii) 9,238 common shares issuable upon exercise of options exercisable within sixty days of December 12, 2025 and (iii)